Literature DB >> 34274736

Should we still only rely on EDSS to evaluate disability in multiple sclerosis patients? A study of inter and intra rater reliability.

Mikael Cohen1, Saskia Bresch2, Océane Thommel Rocchi2, Emmanuel Morain2, Jeanne Benoit2, Michael Levraut2, Salim Fakir2, Cassandre Landes2, Christine Lebrun-Frénay2.   

Abstract

BACKGROUND: Few studies assessed reliability and inter-rater variability of EDSS and functional parameters (FP) rating.
OBJECTIVE: To evaluate inter-rater variability and errors in EDSS and FP rating in junior (JN) and MS Neurologists (MSN).
METHOD: Patients with MS were examined by a JN and a MSN on the same day. Each assessor rated FP and EDSS, then used a smartphone app to get an automated calculation for each FP ("smartphone" FP, sFP) and for EDSS ("smartphone" EDSS, sEDSS) from the description of the neurological exam. Inter-rater variability was assessed comparing JN and MSN ratings for each method. Intra-rater variability was assessed comparing traditional and digital rating for a given assessor. RESULT: 103 patients were included. Perfect agreement between JN and MSN was met for 67% and 70% of patients regarding EDSS and sEDSS. Disagreement that could lead to a significant difference in terms of level of disability occurred in 17% for EDSS and 12% for sEDSS (p=0.07). Regarding intra-rater reliability, we found 38 rating discrepancies for JN and 14 for MSN (p=0.04).
CONCLUSION: We found a significant inter-rater variability as well as a substantial frequency of rating errors in JN. The use of less subjective, easier-to-rate scales should be encouraged.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Digital health; Disability; EDSS; Multiple sclerosis

Year:  2021        PMID: 34274736     DOI: 10.1016/j.msard.2021.103144

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  3 in total

1.  Objective perimetry and progression of multiple sclerosis.

Authors:  Ted Maddess; Corinne F Carle; Emilie M F Rohan; Jonathan Baird-Gunning; Josh P van Kleef; Christian J Lueck
Journal:  eNeurologicalSci       Date:  2022-10-08

Review 2.  Glial Fibrillary Acidic Protein in Blood as a Disease Biomarker of Neuromyelitis Optica Spectrum Disorders.

Authors:  Hyunjin Kim; Eun-Jae Lee; Young-Min Lim; Kwang-Kuk Kim
Journal:  Front Neurol       Date:  2022-03-17       Impact factor: 4.003

Review 3.  MSProDiscuss™ Clinical Decision Support Tool for Identifying Multiple Sclerosis Progression.

Authors:  Tjalf Ziemssen; Jo Vandercappellen; Valeria Jordan Mondragon; Gavin Giovannoni
Journal:  J Clin Med       Date:  2022-07-28       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.